4.385

0.10% -0.025

Humacyte Inc (HUMA)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HUMA Giù? Forum Previsione

Precedente Chiudi:

$4.41

Aprire:

$4.47

Volume 24 ore:

867.71K

Relative Volume:

0.30

Capitalizzazione di mercato:

$555.04M

Reddito:

Utile/perdita netta:

$-110.78M

Rapporto P/E:

-5.0402

EPS:

-0.87

Flusso di cassa netto:

$-75.59M

1 W Prestazione:

-8.98%

1M Prestazione:

-17.50%

6M Prestazione:

-37.33%

1 anno Prestazione:

+80.55%

Intervallo 1D:

$4.365

$4.63

Intervallo di 1 settimana:

$4.15

$5.025

Portata 52W:

$2.43

$9.97

Humacyte Inc Stock (HUMA) Company Profile

Nome

Humacyte Inc

Settore

Healthcare (1195)

Industria

Biotechnology (683)

Telefono

919-313-9633

Indirizzo

2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM

Dipendente

185

Cinguettio

Prossima data di guadagno

2024-11-07

Ultimi documenti SEC

HUMA's Discussions on Twitter

Confronta HUMA con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HUMA	4.40	555.04M	0	-110.78M	-75.59M	-0.87
VRTX	446.39	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	740.49	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.15	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.56	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.47	24.49B	3.30B	-501.07M	1.03B	11.54

Humacyte Inc Stock (HUMA) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-08-14	Aggiornamento	Piper Sandler	Underweight → Neutral
2023-06-22	Iniziato	Cantor Fitzgerald	Overweight
2022-05-16	Downgrade	Piper Sandler	Overweight → Underweight
2021-10-29	Iniziato	Cowen	Outperform
2021-09-24	Iniziato	Oppenheimer	Outperform
2021-09-22	Iniziato	BTIG Research	Buy
2021-09-16	Iniziato	Piper Sandler	Overweight

Mostra tutto

Humacyte Inc Borsa (HUMA) Ultime notizie

10:05 AM

HUMA INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $00,000 In HUMA To Contact Him Directly To Discuss Their Options - PR Newswire

10:05 AM

08:28 AM

Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery - The Manila Times

08:28 AM

08:16 AM

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Malaysian Reserve

Nov 20, 2024

Humacyte CEO Laura Niklason sells $6.6m in common stock - Investing.com

Nov 20, 2024

HUMA LAWSUIT ALERT: Levi & Korsinsky LLP Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - TipRanks

Nov 20, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Business Wire

Nov 20, 2024

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire

Nov 20, 2024

HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 20, 2024

Nov 19, 2024

HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Nov 19, 2024

Blood Vessel Maker Faces Investor Suit Over FDA Findings - Law360

Nov 19, 2024

HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire

Nov 19, 2024

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Humacyte, Inc. - PR Newswire

Nov 19, 2024

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors - Business Wire

Nov 19, 2024

Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights - The Bakersfield Californian

Nov 19, 2024

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

Nov 19, 2024

Shareholder lawsuit shines light on biotech's FDA woes - The Business Journals

Nov 19, 2024

HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Nov 19, 2024

Nov 18, 2024

Humacyte (HUMA) Faces Class Action Lawsuit After FDA Inspection Reveals Manufacturing Issues– Hagens Berman - GlobeNewswire

Nov 18, 2024

HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc. - Business Wire

Nov 18, 2024

Humacyte Presents Preclinical Results of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - The Manila Times

Nov 18, 2024

Humacyte, Inc. Presents Preclinical Results of Small-Diameter ATEV?? for Coronary Artery Bypass Grafting at American Heart Association's Scientific Sessions 2024 - Marketscreener.com

Nov 18, 2024

Nov 15, 2024

Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire

Nov 15, 2024

Humacyte’s (HUMA) Statements to Investors Called Into Question in Light of FDA Violations – Hagens Berman - GlobeNewswire Inc.

Nov 15, 2024